Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy
出版年份 2021 全文链接
标题
Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy
作者
关键词
Lung adenocarcinoma, ERBB2, exon 20 insertion, Chemoimmunotherapy, Efficacy, Response, Prognosis
出版物
LUNG CANCER
Volume 160, Issue -, Pages 50-58
出版商
Elsevier BV
发表日期
2021-08-03
DOI
10.1016/j.lungcan.2021.07.014
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.
- (2020) Florian Guisier et al. Journal of Thoracic Oncology
- Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma
- (2020) Shen Zhao et al. Journal of Thoracic Oncology
- LKB1/STK11 Expression in Lung Adenocarcinoma and Associations with Patterns of Recurrence
- (2020) Kyle G. Mitchell et al. ANNALS OF THORACIC SURGERY
- Impact of SWI/SNF complex mutations in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors: Immuno-oncology biomarker study in LC-SCRUM-Japan (LC-SCRUM-IBIS).
- (2020) Kiyotaka Yoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients with WNT pathway mutations (APC/CTNNB1).
- (2020) Patricia Iranzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
- (2020) Chang Lu et al. Journal of Hematology & Oncology
- Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
- (2020) Chen Lin et al. Frontiers in Oncology
- The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer
- (2020) Adam J Schoenfeld et al. CLINICAL CANCER RESEARCH
- Advances in theranostic biomarkers for tumor immunotherapy
- (2020) Audrey Bellesoeur et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation
- (2020) Haiyong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- 1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program
- (2020) A. Prelaj et al. ANNALS OF ONCOLOGY
- LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
- (2020) M.A. Socinski et al. ANNALS OF ONCOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer
- (2019) Wenfeng Fang et al. CLINICAL CANCER RESEARCH
- Chemoimmunotherapy combination: Potential option for metastatic NSCLC patients with EGFR mutation resistant to osimertinib.
- (2019) Bo Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- 1989PWNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients
- (2019) F J Ros Montana et al. ANNALS OF ONCOLOGY
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
- (2019) Jacqulyne P. Robichaux et al. CANCER CELL
- MA11.06 A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies
- (2019) J. Zhang et al. Journal of Thoracic Oncology
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
- (2018) Conor E. Steuer et al. JOURNAL OF CLINICAL ONCOLOGY
- ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
- (2018) Jianfeng Shen et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- Co-mutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade
- (2018) Jie Wang et al. CANCER RESEARCH
- Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.
- (2018) Marcelo Vailati Negrao et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers.
- (2018) Wei-Chu Victoria Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2018) Hossein Borghaei et al. Journal of Thoracic Oncology
- Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
- (2018) Jingying Nong et al. Nature Communications
- Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
- (2018) Qingzhu Jia et al. Nature Communications
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Method for assessing the similarity between subsets of the T cell receptor repertoire
- (2007) Vanessa Venturi et al. JOURNAL OF IMMUNOLOGICAL METHODS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started